1. Karen S. Marder, MD, MPH

    • Department of Neurology
      Division of Aging and Dementia
    • Department of Psychiatry
      Division of Geriatric Psychiatry
    Headshot

    Karen Marder, MD, MPH is the Sally Kerlin Professor of Neurology at Columbia University Medical Center. She has served as the Chief of the Division of Aging and Dementia since 2001 and has directed the United Council for Neurologic Subspecialties (UCNS) fellowship in Behavioral Neurology and Neuropsychiatry since its inception.

    In both research and patient care, Dr. Marder is focused on the epidemiology and treatment of cognitive, behavioral, and motor impairments in a range of neurodegenerative diseases, including Parkinson’s disease (PD), Huntington’s Disease (HD), HIV dementia, Alzheimer’s disease (AD) and related disorders.

    Since 1998, Dr. Marder has been characterizing the earliest motor and non-motor signs associated with genetic forms of PD. She served as co-chair and chair of the Executive Committee of the Parkinson Study Group (2006-2012), a consortium of North American investigators participating in collaborative PD research at 120 sites. She is the founding (1991) and current director of the multidisciplinary Huntington's Disease Society of America Center of Excellence at Columbia, and also serves as associate director of the Irving Institute for Clinical and Translational Research (CTSA). In addition, Dr. Marder is co-prinicipal investigator of the Columbia University–Weill Cornell NIH-funded NeuroNEXT site, a clinical trial network whose goal is to conduct Phase II biomarker informed neurological clinical trials over a 7-year period.

    I provide diagnosis and treatment for a broad range of cognitive disorders including Alzheimer's disease, mild cognitive impairment, Parkinson's disease, particularly associated with cognitive impairment, dementia with Lewy bodies, frontotemporal dementia and corticobasal degeneration.

    I also see families with Huntington's Disease at the Huntington's Disease Center of Excellence at the NYS Psychiatric Institute.

    CUMC crown logoKaren S. Marder, MD, MPH
    is accepting new patients.
    Call (212) 305-6939 for appointments.

    Provider Information

    One of America's Top Doctors
    One of America's Top Doctors.
    Rated one of New York Magazine's Best Doctors
    Rated One of New York Magazine's
    Best Doctors.

    Board Certifications

    • Neurology

    Clinical Expertise

    • Dementia
    • Huntington Disease
    • Alzheimer's Disease
    • Behavioral Disorder
    • Memory Loss

    Hospital Affiliations

    • NewYork-Presbyterian/Columbia

    Primary Location

    • Neurological Institute of New York

      710 West 168th Street
      Floor: 3
      New York, NY 10032
      Phone:
      (212) 305-6939
      For new and current patient appointments, call:
      (212) 305-6939
      Fax:
      (212) 305-1303

    Insurance Programs

    Please contact the provider’s office directly to verify that your particular insurance is accepted.
    • Aetna [HMO, Medicare, NY Signature, POS, PPO, Signature Administrators, Student Health]
    • Affinity [Essential (Exchange), Medicaid, Medicare]
    • CIGNA [Great West, HMO, POS, PPO]
    • Empire Blue Cross Blue Shield [Blue Priority, Child Health Plus, EPO, HMO, Medicare (Mediblue), NYP Employee Plan, Pathway (Exchange), POS, PPO]
    • Fidelis Care [Child/Family Health Plus, Medicaid, Medicare]
    • Health First [Child/Family Health Plus, Medicaid, Medicare]
    • Health Insurance Plan of NY (HIP) [ConnectiCare, EPO, HMO, Medicaid, Medicare, PPO, Select Care (Exchange), Vytra]
    • Health Plus - Amerigroup [Medicaid]
    • Local 1199
    • MagnaCare
    • Medicare [Medicare]
    • Oxford Health Plans [Freedom, Liberty, Medicare]
    • POMCO
    • UnitedHealthcare [Columbia University Employee Plan, HMO, Medicaid (Community Plan), Medicare, POS, PPO]
    • VNSNY CHOICE [Select Health]

    Biographical Detail

    Academic Appointments

    • Sally Kerlin Professor of Neurology (in the Gertrude H. Sergievsky Center, in the Taub Institute on Alzheimer's Disease and the Aging Brain, and in Psychiatry) at CUMC

    Current Administrative Positions

    • Chief, Division of Aging and Dementia
    • Associate Director, Irving Institute for Clinical and Translational Research
    • Director, Clinical Research Resource, Irving Institute
    • Director, Huntington's Disease Center

    Education And Training

      Education & Training

    • Cornell University Medical College, NY
    • Internship: St. Luke's-Roosevelt Hospital Center
    • Residency: Columbia University Medical Center
    • Fellowship: Columbia University Medical Center

    Gender

    Female
  2. Dr. Marder's research has focused on the epidemiology and treatment of cognitive, behavioral, and motor impairments in a range of neurodegenerative diseases, including Parkinson’s disease (PD), Huntington’s Disease (HD), HIV dementia, and Alzheimer’s disease (AD) and related disorders. Most recently, my focus has been on characterizing the earliest signs associated with genetic forms of PD including Parkin, LRRK2, and GBA mutations, especially in individuals with early-onset PD.

    In May 2006, I was elected to a 6-year term as co-chair of the Executive Committee of the Parkinson Study Group, a consortium of North American investigators participating in collaborative PD research at 120 sites.

    I established the Huntington's Disease Society of America Center of Excellence at Columbia University in 1991, which I continue to lead today. We conduct a wide range of observational research and clinical trials for people with HD and those at risk.

    I am particularly interested in the knowledge and attitudes of people at risk for genetic disorders. At Columbia, I also serve as associate director of the Irving Institute for Clinical and Translational Research (CTSA) where I direct the Clinical Research Resource for adult and pediatric inpatient and outpatient research. I am also the co-Principal Investigator for the Columbia/Weill-Cornell site of the NINDS-funded NeuroNEXT clinical trial network, whose mission is to conduct Phase 2 biomarker informed studies of neurological diseases.

    Research Information

    Research Interests

    • Neuropsychiatry/cognitive disorders

    Grants/Contracts

    • A PHASE 2, DOSE-FINDING, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, EVALUATING THE SAFETY AND EFFICACY OF PRIDOPIDINE 45 MG, 67.5 MG, 90 MG, AND 112.5 MG TWICE-DAILY VERSUS PLACEBO FOR SYMPTOMATIC TREATMENT IN (P&S Industry Clinical Trial)

      Jun 5 2014 - Jun 5 2019

      PARKINSON S PROGRESSION MARKERS INITIATIVE (PPMI) (Private)

      Oct 25 2013 - Feb 17 2019

      COLUMBIA UNIVERSITY MEDICAL CENTER-WEILL CORNELL MEDICAL CENTER NEXT SITE (Federal Gov)

      Sep 30 2011 - Jun 30 2018

      CENTER FOR RESEARCH ON ETHICAL, LEGAL AND SOCIAL IMPLICATIONS OF PSYCHIATRIC, NEUROLOGIC AND BEHAVIORAL GENETICS (Federal Gov)

      May 3 2013 - May 31 2018

      PBMC AND URINE EXOSOSMES IN LRRK2 AND IDIOPATHIC PD (Private)

      Jan 1 2016 - Dec 31 2017

      IDENTIFYING HUNTINGTONS DISEASE MARKERS BY MODERN STATISTICAL LEARNING METHODS (Federal Gov)

      Aug 1 2014 - Jul 31 2017

      NORTHERN MANHATTAN INITIATIVE FOR MINORITY INVOLVEMENT IN CLINICAL TRIALS (Federal Gov)

      Aug 8 2012 - Jun 30 2017

      ANALYSIS AND REPLICATION OF A GENETIC INTERACTION BETWEEN LRRK2 AND PARK16 (Private)

      Oct 2 2013 - Jul 31 2016

      FDG PET STUDY START-UP (Private)

      Jul 1 2015 - Jun 30 2016

      EFFICIENT METHODS FOR GENOTYPE-SPECIFIC DISTRIBUTIONS WITH UNOBSERVED GENOTYPES (Federal Gov)

      Jul 15 2011 - Jun 30 2016

      CLINICAL AND TRANSLATIONAL SCIENCE AWARD (Federal Gov)

      Sep 30 2006 - Jun 30 2016

      HDSA CENTER OF EXCELLENCE (Private)

      Jan 1 2015 - Dec 31 2015

      PENETRANCE OF LRRD2 IN THE MJ FOX LRRK2 COHORT CONSORTIUM (Private)

      Sep 18 2013 - Sep 17 2015

      CREATINE SAFETY, TOLERABILITY & EFFICACY IN HUNTINGTON S DISEASE: CREST-E (Federal Gov)

      Jul 1 2014 - Jun 30 2015

      PARKINSON S DISEASE, ASHKENAZI JEWS AND LRRK2: A CONSORTIUM PROPOSAL (Private)

      Jul 1 2011 - Jun 30 2015

      ALZHEIMER S DISEASE RESEARCH CENTER AT COLUMBIA UNIVERSITY (Federal Gov)

      Jun 1 2010 - May 31 2015

      HORIZON-PLUS: AN OPEN LABEL EXTENSION OF THE HORIZON PROTOCOL(DIM20) EVALUATING THE SAFETY OF DIMEBON(LATREPIRDINE) IN S (P&S Industry Clinical Trial)

      May 27 2010 - May 27 2015

      DAT IMAGING IN AJ LRRK2 GENE CARRIERS (LRKK2) (Private)

      Dec 13 2010 - Apr 18 2015

      ANALYTIC MODELS AND BIOMARKER DEVELOPMENT (Private)

      Jan 1 2012 - Dec 31 2014

      ASHKENAZI JEWS AND LRRK2 (SUBCONTRACT WITH BIMC) (Private)

      Nov 1 2013 - Oct 31 2014

      NEUROBIOLOGICAL PREDICTORS OF HUNTINGTON S DISEASE (Private)

      Sep 1 2012 - Aug 31 2014

      A PROSPECTIVE REGISTRY STUDY IN A GLOBAL HUNTINGTON S DISEASE COHORT (ENROLL-HD) (Private)

      Aug 21 2012 - Aug 20 2014

      COENZYME Q10 IN HUNTINGTON S DISEASE (Federal Gov)

      Sep 30 2012 - Jul 31 2014

      LRRK2 MUTATIONS AND CANCER RISK (Private)

      May 1 2012 - Apr 30 2014

      CENTER FOR ELSI RESEARCH ON PSYCHIATRIC, NEUROLOGIC, AND BEHAVIORAL GENETICS (Federal Gov)

      Jun 1 2010 - Apr 30 2014

      NEUROPATHOLOGICAL TISSUE COLLECTION IN LRRK2 MUTATION CARRIERS WITH AND WITHOUT PARKINSON S DISEASE (Private)

      Feb 16 2012 - Feb 15 2014

      HUNTINGTON S DISEASE SOCIETY OF AMERICA CENTER OF EXCELLENCE (Private)

      Oct 1 2004 - Dec 31 2013

      GAIT AND MOTOR SYMPTOMS IN HEALTHY ASYMPTOMATIC RELATIVES OF PATIENTS WITH PD CARRIERS OF MUTATIONS IN THE LRRK2 GEN (Private)

      Dec 1 2011 - Nov 30 2013

      GENETIC EPIDEMIOLOGY OF PARKINSON S DISEASE (Federal Gov)

      Jul 1 1998 - Nov 30 2013

      NEUROBIOLOGICAL PREDICTORS OF HUNTINGTON S DISEASE (Federal Gov)

      Sep 1 2004 - Aug 31 2013

      NEUROBIOLOGICAL PREDICTORS OF HUNTINGTON''S DISEASE (Federal Gov)

      Sep 1 2004 - Aug 31 2013

      CREATINE SAFETY, TOLERABILITY & EFFICACY IN HUNTINGTON S DISEASE (CREST-E) (Federal Gov)

      Jul 1 2008 - Jun 30 2013

      PARKINSON S DISEASE GENETICS INITIATIVE (Private)

      Jul 1 2005 - Jun 30 2013

      AUTONOMIC DYSFUNCTION IN LRRK2 MUTATION CARRIERS: CHARACTERIZATION OF AUTONOMIC PROFILES OF PATIENTS WITH PD, CARRIERS OF MUTATIONS IN THE LRRK2 GENE AND NON-MANIFESTING FIRST DEGREE RELATIVES (Private)

      Dec 1 2011 - Nov 30 2012

      COGNITIVE ASSESSMENT BATTERY (CAB) BETA STUDY (Private)

      Feb 18 2011 - Nov 30 2012

      COENZYME Q10 IN HUNTINGTON S DISEASE (Federal Gov)

      Dec 1 2007 - Nov 30 2012

      THE ROLE OF GLUCOCEREBROSIDASE IN PARKINSON DISEASE AND COGN ITIVE IMPAIRMENT (Private)

      Jul 1 2010 - Aug 31 2012

      PARKINSON''S DISEASE IPS CELL LINE RESEARCH (Federal Gov)

      Sep 30 2009 - Aug 31 2012

      PARKINSON S DISEASE, ASHKENAZI JEWS AND LRRK2-A CONSORTIUM PROPOSAL (Private)

      Jun 30 2009 - Jun 29 2012

      COOPERATIVE HUNTINGTON"S OBSERVATIONAL RESEARCH TRIAL (COHOT) (Private)

      Jul 1 2005 - Jun 30 2011

      PROSPECTIVE HUNTINGTON AT RISK OBSERVATION (Federal Gov)

      Aug 17 2004 - Jun 30 2011

      PROSPECTIVE HUNTINGTON AT RISK OBSERVATION STUDY (Federal Gov)

      Aug 17 2004 - Jun 30 2011

      COOPERATIVE HUNTINGTON''S OBSERVATIONAL RESEARCH TRIAL (COHOR T) (SUBSTUDY) (Private)

      Jul 1 2009 - Jun 30 2010

      PROSPECTIVE HUNTIGTON AT RISK OBSERVATION STUDY__PHAROS (Private)

      Jul 1 2006 - Jun 30 2010

      PROSPECTIVE HUNTINGTON AT RISK OBSERVATION STUDY--PHAROS (Federal Gov)

      Jul 1 2006 - Jun 30 2010

      PARKINSONS DISEASE COLLABORATIVE STUDY OF GENETIC LINKAGE, P ROGENI (Federal Gov)

      Sep 1 2000 - Jan 31 2010

      NEUROBIOLOGICAL PREDICTORS OF HUNTINGTON''S DISEASE (Private)

      Aug 1 2003 - Aug 31 2009

      RESPONCE OF A SAMPLE POPULATION WITH THE DELETERIOUS HD ALLELE, RESPOND-HD (Federal Gov)

      Sep 26 2005 - Jul 31 2009

      GENETIC EPIDEMIOLOGY OF PARKINSON"S DISEASE (Federal Gov)

      Jul 1 1998 - Apr 30 2009

      COENZYME Q10 IN HUNTINGTON''S DISEASE (Federal Gov)

      Dec 1 2007 - Dec 10 2008

      NEUROLOGICAL AIDS RESEARCH CONSORTIUM (Federal Gov)

      Dec 1 1993 - Jul 31 2007

      NEUROBIOLOGICAL PREDICTORS OF HUNTINGTON''S DISEASE (Federal Gov)

      Mar 1 2002 - Aug 31 2004

  3. publications

    For a complete list of publications, please visit PubMed.gov